1
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Condition(s):PTCL; CTCLLast Updated:July 19, 2022Recruiting
Folotyn, AREA[OverallStatus], Open or Pending: 5 Clinical Trials
Include Studies Not Open or Pending
2
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Condition(s):Anaplastic Large Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Enteropathy-Associated T-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hepatosplenic T-Cell Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Enteropathy-Associated T-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Hepatosplenic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Subcutaneous Panniculitis-Like T-Cell LymphomaLast Updated:August 12, 2021Recruiting
3
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Condition(s):Lymphoma, T-CellLast Updated:March 31, 2022Recruiting
4
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator’s Choice in PTCL
Condition(s):PTCLLast Updated:March 2, 2022Recruiting
5
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Condition(s):NK-Cell Lymphoma; NK-Cell Leukemia; Peripheral T Cell LymphomaLast Updated:September 2, 2021Recruiting